BioVie Inc (NAS:BIVI)
$ 2.8 0.09 (3.32%) Market Cap: 49.75 Mil Enterprise Value: 33.44 Mil PE Ratio: 0 PB Ratio: 1.58 GF Score: 31/100

BioVie Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript

Apr 28, 2022 / 05:30PM GMT
Release Date Price: $38.5 (-5.41%)
Mayank Mamtani
B. Riley Securities, Inc. - Analyst

Good afternoon and good morning for folks here on the West Coast. Thank you for joining us today for our next fireside chat with BioVie's President and CEO, Cuong Do; and Chief Medical Officer, Dr. Joseph Palumbo. Appreciate you guys joining us and being part of the conference.

Understand BioVie has a lot going on in terms multiple therapeutic area of focus. Obviously, today is a conversation mainly focused on the neuroscience side of things. But why don't we get started, Cuong, with you giving us an overview of the company and the pipeline before we get deeper into the neuroscience efforts?

Cuong Do
BioVie Inc. - President & CEO

Perfect. Mayank, thank you so much for having us today. And you guys are all aware of this thing. Since we are a public company, I'm required to essentially make a statement about forward-looking disclosures. I'll forego reading it since everybody who is here is very experienced with that. So let's just dive right in.

BioVie is currently developing two

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot